ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.

Quote:

Search for Ticker

Free Membership

Search:

AVNR: Avanir Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

AVANIR PHARMACEUTICALS INC (NASD)
AVNR	1.73	0.02	(1.17%)	Vol. 596,228	16:00 ET

AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, cardiovascular disorders, inflammation and infectious diseases. AVANIR currently markets FazaClo, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatments for schizophrenia. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. AVANIR has an ongoing development program with Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. The Company's first commercialized product, Abreva, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.

General Information

AVANIR PHARM

101 Enterprise Suite 300 Aliso Viejo, CA 92656 Phone: 949 389-6700 Fax: - Web: www.avanir.com Email: ir@avanir.comp

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	September
Last Reported Quarter	12/31/09
Next EPS Date	05/06/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	1.71
52 Week High	4.09
52 Week Low	0.25
Beta	2.46
20 Day Moving Average	599,483.56
Target Price Consensus	N/A

% Price Change
4 Week	-11.40
12 Week	-10.47
YTD	-10.00

% Price Change Relative to S&P 500
4 Week	-4.68
12 Week	-6.85
YTD	-4.22

Share Information
Shares Outstanding (millions)	83.18
Market Capitalization (millions)	142.23
Short Ratio	7.91
Last Split Date	01/18/2006

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.07
Current Year EPS Consensus Estimate	-0.28
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	05/06/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	3.00
60 Days Ago	3.00
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	14.29%
vs. Previous Quarter	33.33%

Sales Growth
vs. Previous Year	-16.67%
vs. Previous Quarter:	50.00%

Price Ratios
Price/Book	8.90
Price/Cash Flow	-
Price / Sales	36.44

ROE
12/31/09	-122.55
09/30/09	-111.84
06/30/09	-92.17

ROA
12/31/09	-68.93
09/30/09	-64.04
06/30/09	-54.17

Current Ratio
12/31/09	5.30
09/30/09	5.57
06/30/09	5.24

Quick Ratio
12/31/09	5.28
09/30/09	5.55
06/30/09	5.24

Operating Margin
12/31/09	-555.98
09/30/09	-525.82
06/30/09	-461.05

Net Margin
12/31/09	-554.45
09/30/09	-527.34
06/30/09	-460.14

Pre-Tax Margin
12/31/09	-554.45
09/30/09	-527.34
06/30/09	-460.14

Book Value
12/31/09	0.19
09/30/09	0.25
06/30/09	0.19

Inventory Turnover
12/31/09	1.20
09/30/09	2.29
06/30/09	56.97

Debt-to-Equity
12/31/09	0.00
09/30/09	0.00
06/30/09	0.00

Debt to Capital
12/31/09	0.00
09/30/09	0.00
06/30/09	0.00


About Zacks \| Advertise \| Affiliate \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2010 Zacks Investment Research